Back to today’s briefing

Story perspectives

Novartis' Cosentyx Faces Setback in Autoimmune Trial

7/4/2025

30 7

Summary

Story summary

Novartis' Cosentyx stumbled in a Phase III trial for giant cell arteritis, casting doubt on the effectiveness of IL-17A inhibitors in treating autoimmune diseases. As rivals like Roche's Actemra and AbbVie's Rinvoq lead the market, this setback forces investors to rethink their strategies, even as Cosentyx continues to thrive in psoriasis and other areas.

1 of 1

Story summary

Novartis' Cosentyx stumbled in a Phase III trial for giant cell arteritis, casting doubt on the effectiveness of IL-17A inhibitors in treating autoimmune diseases. As rivals like Roche's Actemra and AbbVie's Rinvoq lead the market, this setback forces investors to rethink their strategies, even as Cosentyx continues to thrive in psoriasis and other areas.